SGLT2 Inhibitor Improves HbA1c and More in T2D and Overweight, Obesity
Diabetes will be discussed at Consultant360’s new Practical Updates in Primary Care 2020 meeting. For more information about the meeting and to register, click here.
Treatment with the selective sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin appears to be safe, effective, and well-tolerated among patients with type 2 diabetes and overweight or obesity, according to new findings.
Researchers arrived at their conclusion after pooling and assessing data from 3 placebo‐controlled, randomized, Phase 3 studies of ertugliflozin. Participants included in the present analysis had been treated with ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo. Participants with a body mass index (BMI) of at least 25 kg/m2, which constituted 1377 (89%) of 1544 patients, were stratified by BMI subgroup.
From baseline to week 26 of treatment with ertugliflozin compared with placebo, the researchers had observed greater decreases in:
- Glycated hemoglobin A1c (HbA1c)
- Fasting plasma glucose
- Body weight (BW)
- Systolic blood pressure (SBP)
The researchers noted that decreases in HbA1c were consistent in all subgroups, and that percent BW changes reductions similar in all BMI subgroups.
The incidence of adverse events was found to be 44.6% in participants who received ertugliflozin 5 mg, 50.1% in those treated with ertugliflozin 15 mg, and 52.5% in those who received placebo.
Ertugliflozin is currently approved by the US Food and Drug Administration as an adjunct therapy to diet and exercise for the improvement of glycemic control in adults with type 2 diabetes.
Heymsfield SB, Raji A, Gallo S, et al. Efficacy and safety of ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. Obesity. 2020;28(4):724-732. https://doi.org/10.1002/oby.22748.